Q-omics provides the consensus-scored TFE3 profile across patient tissues and cancer cell-line models. TFE3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TFE3 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, TFE3 RNA expression shows 19,747 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and HNSC as cancer lineages where TFE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFE3 survival associations across molecular data types. TFE3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFE3 RNA expression–survival associations across cancer types. High TFE3 expression shows unfavorable associations in KIRP, UVM, LIHC, COAD and LGG, but favorable associations in ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for TFE3 RNA expression.
This table summarizes TFE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TFE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFE3 shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher TFE3 RNA expression in tumor versus normal tissue (log2 FC = +0.819, t-test p < 0.001).
This table shows molecular features associated with TFE3 in patient tissues and cancer cell lines. In patient samples, TFE3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TFE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
